Human MCP-2 (CCL8) Recombinant

/, CCL chemokines/Human MCP-2 (CCL8) Recombinant

Human MCP-2 (CCL8) Recombinant


accession P80075

Source Optimized DNA sequence encoding HumanMCP-2(CCL8) mature chain was expressed in Escherichia Coli.
Molecular weight Human MCP-2, generated by the proteolytic removal of the signal peptide and propeptide and has a calculated molecular mass of approximately9 kDa. RecombinantMCP-2 is a monomeric protein consisting of77amino acid residue subunits and migrates as an approximately9 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE.
Purity >98%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the dose-dependent chemo-attraction of THP1 leukemic cells and was found to be ≤ ng/ml, corresponding to a specific activity of >x units/mg.
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation MCP-1was lyophilized from a.2 μm filteredmM PB solution pH.5,mM NaCl.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor P51681
Interactor P32246
Interactor P41597
Interactor Q9NPB9
Biological Process Chemotaxis
Biological Process Inflammatory-response
Molecular function Cytokine
Molecular function Heparin-binding


Degradation of MCPs

  • Recombinant human CCL2, CCL7, CCL8 and CCL13 possessing an N-terminal glutaminyl residue were dissolved in 25 mM Tris/HCl pH 7.6 at a final concentration of 10 µg/ml.
  • MCPs were either pre-incubated with recombinant human QC (0.6 µg/mlet al, 1-76) was either pre-incubated with recombinant human QC and subsequently incubated with human plasma or incubated with human plasma without QC.
  • All samples were analysed using Maldi-TOF-MS.